Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Gold Price Hits Two-Month High as Investors Await US Inflation Data 
Oil Prices Rise as Hormuz Tensions Threaten Global Supply 
CBA Posts Record A$10.98B Profit Despite Cautious Outlook 
Samsung, SK Hynix Shares Surge on Report of Potential Temasek Investment 
Canada, US Hold Fresh Trade Talks as August 19 Tariff Deadline Nears 
Gold Prices Rise as Fed Rate Hike Bets Ease 
Asian Stocks Mixed as RBA Holds Rates, Oil Risks Rise 
Iran War Escalates as US, Houthis Target Ships Near Key Oil Routes 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
European Stocks Flat as Oil Prices Rise, US CPI in Focus 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
KOSPI Rebounds 20% as Samsung, SK Hynix Lead South Korea Stock Rally 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Samsung Biologics is said to be most likely to sign a deal with Moderna, an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. The contract is for the production of COVID-19 vaccine in South Korea.
Samsung and Moderna’s anticipated announcement
As per The Korea Herald, Samsung Biologics and Moderna may work together to boost vaccine production amid the vaccine shortage in the country. It was reported that the two companies may formally announce their deal at the summit where S. Korea’s President Moon Jae In and US President Joe Biden are set to meet.
A local TV station was said to have reported about the possibility of this business negotiation last weekend. Other media outlets followed suit and shared related reports.
In any case, Samsung Biologics did not confirm if it will indeed sign a contract with Moderna for vaccine production and supply. It was quite vague as the Incheon-based biotechnology company did not deny the reports as well. In a regulatory filing, there was a statement saying there is no decision yet about Moderna’s COVID-19 being manufactured in S. Korea.
The guessing game
There have been lots of reports as to which company that Moderna will partner with as it is reported to be very interested in producing its vaccine in the said Asian region. Various firms were mentioned, and initial rumor is that it will work with Hanmi Pharmaceuticals or GC Pharma.
And now, the most promising candidate for a deal with Moderna is reportedly Samsung Biologics that was suddenly added to the list of potential partners. Moderna’s CEO, Stephane Bancel, may visit S. Korea this month to survey as per the reports.
Maeil Business News pointed out that it was also reported earlier that Samsung Biologics will produce Pfizer vaccine but this was vehemently denied but with Moderna, it was different as the Korean firm would not acknowledge or deny and only saying that “nothing has been finalized yet.”
Thus, it was speculated that Samsung Biologics and Moderna are more likely to confirm their contract soon. The rumors of the partnership were heightened by the fact that the American pharma already started looking for senior executives for its office that will soon open in Korea.
